Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma
Authors
Keywords
-
Journal
Immunotherapy
Volume 11, Issue 1, Pages 21-35
Publisher
Future Medicine Ltd
Online
2018-12-07
DOI
10.2217/imt-2018-0097
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy
- (2018) José I. López et al. PATHOLOGY RESEARCH AND PRACTICE
- Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
- (2018) Rawad Elias et al. Journal for ImmunoTherapy of Cancer
- Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression
- (2018) Hayriye Tatli Dogan et al. Diagnostic Pathology
- Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma
- (2018) Kosuke Ueda et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma
- (2016) Shanthini M. Crusz et al. BMC Medicine
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
- (2016) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages
- (2016) Thibault Vieira et al. LUNG CANCER
- PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises
- (2015) F. Massari et al. CANCER TREATMENT REVIEWS
- Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
- (2015) N. A. Giraldo et al. CLINICAL CANCER RESEARCH
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
- (2015) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation
- (2015) R. W. Joseph et al. Cancer Immunology Research
- Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
- (2015) M. Callea et al. Cancer Immunology Research
- Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
- (2014) T. K. Choueiri et al. CLINICAL CANCER RESEARCH
- Extracranial oligometastatic renal cell carcinoma: current management and future directions
- (2014) Jasmin Loh et al. Future Oncology
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
- (2014) Marco Gerlinger et al. NATURE GENETICS
- Tumor-infiltrating PD1-Positive Lymphocytes and FoxP3-Positive Regulatory T Cells Predict Distant Metastatic Relapse and Survival of Clear Cell Renal Cell Carcinoma
- (2014) Myoung Jae Kang et al. Translational Oncology
- PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases
- (2014) L.B. Jilaveanu et al. Journal of Cancer
- Inverse Association between Programmed Death Ligand 1 and Genes in the VEGF Pathway in Primary Clear Cell Renal Cell Carcinoma
- (2013) R. W. Joseph et al. Cancer Immunology Research
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Intratumoral FOXP3-positive Regulatory Immune Cells during Interleukin-2 Treatment in Metastatic Renal Cell Carcinoma
- (2009) H. K. Jensen et al. CLINICAL CANCER RESEARCH
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More